Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,296 Mln
P/E Ratio
--
P/B Ratio
10.49
Industry P/E
--
Debt to Equity
0.08
ROE
-0.67 %
ROCE
-60.46 %
Div. Yield
0 %
Book Value
1.92
EPS
-0.9
CFO
$-250.22 Mln
EBITDA
$-332.15 Mln
Net Profit
$-335.96 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pulse Biosciences Inc (DE) (PLSE)
| 2.24 | 7.23 | -7.92 | 147.57 | 86.82 | 11.71 | -- |
|
BSE Sensex*
| 2.70 | 3.81 | 4.69 | 7.62 | 12.09 | 19.69 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Pulse Biosciences Inc (DE) (PLSE)
| 41.83 | 341.88 | -81.30 | -37.93 | 77.93 | 17.02 | -51.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.69 | 10,202.62 | 12.01 | 12.69 | |
| 72.33 | 10,025.34 | 96.83 | 2.52 | |
| 163.14 | 8,863.93 | -- | -25.23 | |
| 296.91 | 11,513.99 | 277.87 | 3.65 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft... tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131 Read more
Executive Chairman
Mr. Robert W. Duggan
Executive Chairman
Mr. Robert W. Duggan
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pulse Biosciences Inc (DE) (PLSE) stood at $ 132 Mln as on 31-Dec-24
The share price of Pulse Biosciences Inc (DE) (PLSE) is $17.80 (NASDAQ) as of 29-Apr-2025 16:07 EDT. Pulse Biosciences Inc (DE) (PLSE) has given a return of 86.82% in the last 3 years.
Pulse Biosciences Inc (DE) (PLSE) has a market capitalisation of $ 1,296 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pulse Biosciences Inc (DE) (PLSE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pulse Biosciences Inc (DE) (PLSE) and enter the required number of quantities and click on buy to purchase the shares of Pulse Biosciences Inc (DE) (PLSE).
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131
The CEO & director of Mr. Robert W. Duggan. is Pulse Biosciences Inc (DE) (PLSE), and CFO & Sr. VP is Mr. Robert W. Duggan.
There is no promoter pledging in Pulse Biosciences Inc (DE) (PLSE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Pulse Biosciences Inc (DE) (PLSE) | Ratios |
|---|---|
|
Return on equity(%)
|
-67.31
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pulse Biosciences Inc (DE) (PLSE) was $0 Mln.
$-0.15
(
